A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
GUIDED THERAPEUTICS INC
GTHP
$22M
Mkt Cap
$0.26
-3.70%
GUIDED THERAPEUTICS INC (GTHP) has a 5-year average return on invested capital (ROIC) of -90.8%. This is below average and may indicate limited pricing power.
GUIDED THERAPEUTICS INC (GTHP) has a market capitalization of $22M. It is classified as a small-cap stock.
GUIDED THERAPEUTICS INC (GTHP) does not currently pay a regular dividend.
GUIDED THERAPEUTICS INC (GTHP) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
GUIDED THERAPEUTICS INC (GTHP) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
GUIDED THERAPEUTICS INC (GTHP) reported earnings per share (EPS) of $-0.04 in its most recent fiscal year.
GUIDED THERAPEUTICS INC (GTHP) has a return on equity (ROE) of 61.4%. This indicates the company generates strong returns for shareholders.
We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -3.3M | -3.3M | -2.6M | -3.8M | -5.0M | -2.4M |
| EPS | $-0.04 | $-0.04 | $-0.05 | $-0.07 | $-0.15 | $-0.18 |
| Free Cash Flow | -1.1M | -1.1M | -1.1M | -1.7M | -1.5M | -1.6M |
| ROIC | -141.5% | 0.0% | -120.9% | -163.6% | -78.2% | -91.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.15 | -0.10 | -0.08 | -0.13 | -0.08 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -2.4M | -2.4M | -2.1M | -3.5M | -3.3M | -2.4M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | 61.4% | 59.6% | 112.4% | 119.4% | 29.8% |
| Shares Outstanding | 84M | 84M | 52M | 54M | 33M | 14M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 65K | N/A | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | -204.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 2.8M | 1.5M | 733K | 334K | 244K | 122K | 143K | 69K | 77K | 228K | 526K | 469K | 469K |
| SG&A | 4.6M | 4.1M | 2.8M | 2.3M | 1.1M | 694K | 913K | 2.2M | 3.0M | 3.0M | 1.3M | 2.3M | 2.3M |
| EBIT | -8.7M | -6.2M | -3.8M | -3.1M | -1.5M | -937K | -1.1M | -2.4M | -3.3M | -3.5M | -2.1M | -2.4M | -2.4M |
| Op. Margin | -13336.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | N/A | -9.5M | N/A | -11M | 900K | -1.9M | -401K | -2.4M | -5.0M | -3.8M | -2.6M | -3.3M | -3.3M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 40K | 26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 178K | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | N/A | -195.6% | N/A | N/M | N/M | -62.7% | -61.6% | -91.5% | -78.2% | -163.6% | -120.9% | 0.0% | -141.5% |
| ROE | N/A | 189.5% | N/A | 76.6% | -5.1% | 11.7% | 2.9% | 29.8% | 119.4% | 112.4% | 59.6% | 61.4% | 0.0% |
| ROA | N/A | -342.7% | N/A | -1156.4% | 280.4% | -271.3% | -31.7% | -143.4% | -183.9% | -149.3% | -170.1% | -247.7% | -252.7% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 0 | 0 | -1.8M | -1.1M | 1.4M | -806K | -1.9M | -1.6M | -1.5M | -1.7M | -1.1M | -1.1M | -1.1M |
| Free Cash Flow | N/A | N/A | -1.8M | -1.1M | 1.4M | -806K | -1.9M | -1.6M | -1.5M | -1.7M | -1.1M | -1.1M | -1.1M |
| Owner Earnings | -2.1M | -2.1M | -3.1M | -1.4M | 1.3M | -835K | -2.2M | -1.8M | -2.9M | -3.6M | -1.2M | -1.5M | -1.5M |
| CapEx | 0 | 8K | 0 | 0 | 0 | 0 | 1K | 14K | 31K | 0 | 0 | 2K | 2K |
| Maint. CapEx | 1.2M | 1.1M | 1.2M | 213K | 27K | 21K | 0 | 1K | 4K | 9K | 9K | 10K | 10K |
| Growth CapEx | N/A | 0 | N/A | N/A | N/A | N/A | N/A | 13K | 27K | N/A | N/A | 0 | 0 |
| D&A | 1.2M | 1.1M | 1.2M | 213K | 27K | 21K | 0 | 1K | 4K | 9K | 9K | 10K | 10K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 886K | 1.0M | 95K | 59K | 44K | 8K | 310K | 228K | 1.4M | 1.8M | 120K | 377K | 377K |
| Debt Repayment | 452K | 48K | 0 | 0 | 0 | 0 | 0 | 86K | 221K | 0 | 29K | 30K | 30K |
| Balance Sheet | |||||||||||||
| Net Debt | 1.8M | 784K | 3.8M | 9.8M | 6.1M | -121K | 290K | -203K | -1.9M | -288K | 116K | 857K | 857K |
| Cash & Equiv. | 162K | 35K | 14K | 1K | 0 | 899K | 182K | 643K | 2.3M | 591K | 388K | 63K | 63K |
| Long-Term Debt | 783K | 0 | 2.4M | 8.0M | 5.1M | 0 | 23K | 22K | 0 | 57K | 92K | 82K | 82K |
| Debt/Equity | -0.44 | -0.15 | -0.41 | -0.51 | -0.39 | -0.05 | -0.04 | -0.08 | -0.13 | -0.08 | -0.10 | -0.15 | 0.00 |
| Interest Coverage | -8.9 | -4.7 | -2.0 | -2.8 | -0.9 | -0.7 | -1.0 | -2.1 | -5.7 | -12.4 | -5.5 | -3.8 | -3.8 |
| Equity | -4.5M | -5.6M | -9.3M | -19M | -16M | -17M | -11M | -5.4M | -2.9M | -3.8M | -4.9M | -6.0M | -6.0M |
| Total Assets | 3.0M | 2.5M | 1.5M | 406K | 236K | 1.2M | 1.4M | 2.0M | 3.4M | 1.7M | 1.4M | 1.3M | 1.3M |
| Total Liabilities | 7.5M | 8.1M | 11M | 20M | 16M | 18M | 12M | 7.5M | 6.2M | 5.5M | 6.3M | 7.3M | 7.3M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | -113M | -123M | -128M | -139M | -138M | -140M | -140M | -142M | -147M | -151M | -154M | -157M | -157M |
| Working Capital | -2.8M | -3.3M | -8.3M | -12M | -11M | -11M | -8.1M | -4.1M | -1.9M | -3.4M | -5.0M | -6.0M | -6.0M |
| Current Assets | 1.8M | 2.1M | 1.0M | 297K | 196K | 1.0M | 896K | 1.6M | 3.0M | 1.4M | 1.2M | 605K | 605K |
| Current Liabilities | 4.6M | 5.5M | 9.3M | 12M | 11M | 12M | 9.0M | 5.7M | 4.9M | 4.8M | 6.2M | 6.6M | 6.6M |
| Per Share Data | |||||||||||||
| EPS | -5.16 | -1,254,999.37 | -8.44 | -1,214.62 | 16,185.84 | -192.93 | -0.04 | -0.18 | -0.15 | -0.07 | -0.05 | -0.04 | -0.04 |
| Owner EPS | -8.69 | -272,314.92 | -1,598.98 | -156.72 | 23,271.64 | -83.86 | -0.22 | -0.13 | -0.09 | -0.07 | -0.02 | -0.02 | -0.02 |
| Book Value | -18.26 | -734,537.14 | -4,748.75 | -2,147.44 | -284,582.99 | -1,700.81 | -1.08 | -0.40 | -0.09 | -0.07 | -0.09 | -0.07 | -0.07 |
| Cash Flow/Share | N/A | N/A | -923.51 | -126.62 | 24,548.52 | -80.95 | -0.19 | -0.12 | -0.04 | -0.03 | -0.02 | -0.01 | -0.04 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.2M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 10.0M | 13.5M | 33.1M | 53.7M | 51.8M | 83.7M | 83.7M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.9% | -13.0% | -22.6% | -14.3% | N/A | -4.9% |
| Market Cap | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 27M | 12M | 7.7M | 7.8M | 0 | 22M |
| Avg. Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.63 | 0.51 | 0.21 | 0.14 | 0.00 | 0.26 |
| Year-End Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.54 | 0.35 | 0.14 | 0.15 | 0.00 | 0.26 |
GUIDED THERAPEUTICS INC passes 1 of 9 quality checks, indicating weak fundamentals.
The Ledger Terminal provides 16 years of financial data for GUIDED THERAPEUTICS INC (GTHP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GUIDED THERAPEUTICS INC (GTHP) has a book value per share of $-0.07, based on its most recent annual SEC filing.